Extracorporeal cardiopulmonary resuscitation often requires interruptions to chest compression (CC); the possible impact on survival and neurological outcomes has been unknown. This cohort study included all index paediatric IHCAs â„1 min in Pediatric Resuscitation Quality (PediRES-Q), a worldwide collaborative network, from July 2015 through December 2019. Age was by definition <18 years. Favourable neurological outcome was defined as Pediatric Cerebral Performance Category (PCPC) â€3 at discharge or no change from baseline.
A total of 371 index IHCAs were identified. Median (Q1, Q3) age was 2.6 (0.6â9.4) years, 46% were girls, 13% had shockable rhythm, CPR duration was 23 (9â47) minutes. The longest pause had a median length of 17 (8â27) seconds. Each increment of 5 seconds in longest CC interruption was associated with 6% lower odds for survival with favourable neurological outcome. This held true even after adjusting for the following established confounders: age, defibrillation, intubation, extracorporeal CPR, illness category, hypotension as aetiology for arrest, and CC depth, as well as clustering by location (adjusted OR 0.94; 95% CI 0.88â0.99; P=0.04). The longest CC interruption was found to be associated with lower odds for survival to hospital discharge (adjusted OR 0.94; 95% CI 0.90â0.99; P=0.02) and for return of spontaneous circulation (adjusted OR 0.91; 0.86â0.96; P=0.001).
- Lauridsen KG, et al. Chest Compression Pause Duration is Associated with Worse Survival Outcomes Following Pediatric In-hospital Cardiac Arrest. Abstract 124, AHA Scientific Sessions 2020, 13-17 Nov.
Posted on
Previous Article
« Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque Next Article
Dobutamine versus milrinone in cardiogenic shock »
« Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque Next Article
Dobutamine versus milrinone in cardiogenic shock »
Table of Contents: AHA 2020
Featured articles
COVID-19 and Influenza
Fewer CV complications than expected in AHA COVID-19 Registry
Worse COVID-19 outcomes in younger obese patients
Effects of CVD in hospitalised COVID-19 patients
Unfavourable outcomes for COVID-19 patients with AF and atrial flutter
High-dose influenza vaccine in patients with CVD
Atrial Fibrillation
Vitamin D or omega 3 fatty acids do not prevent AF
Active screening for AF improves clinical outcomes
AF screening in older adults at primary care visits
CVD Risk Reduction
Clever trial design gets patients back on statins: the SAMSON trial
Polypill plus aspirin reduces cardiovascular events
Lowering LDL cholesterol in older patients is beneficial
No CV benefit from omega 3 in high-risk patients
Safety and efficacy of inclisiran for hypercholesterolemia
Remote risk management programme effective and efficient
Healthy lifestyle lowers mortality irrespective of medication burden
Heart Failure
Omecamtiv mecarbil improves outcomes in HFrEF-patients
IV iron reduces HF hospitalisation
Dapagliflozin reduces renal risk independent of CV disease status
âStrongly consider an SGLT2-inhibitor in most T2DM patientsâ
Additional HFrEF education and patient-engagement tools
Acute Coronary Syndrome
No benefit from omega-3 fatty acids after recent MI
PIONEER III trial: Drug-eluting stents comparable
Coronary and Valve Disease
Extra imaging reveals cause of MINOCA in women
Ticagrelor not superior to clopidogrel after elective PCI
Stroke
Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque
AF monitoring following cardiovascular surgery
Miscellaneous
PAD: Rivaroxaban reduces VTE risk after revascularisation
Sotatercept: potential new treatment option for PAH
Finerenone lowers CV events in diabetic CKD patients
Mavacamten effective in obstructive hypertrophic cardiomyopathy
Children exposed to tobacco smoke have worse heart function as adults
Transgender people have unaddressed heart disease risks
Intensive blood pressure lowering benefits older adults
Longer chest compression pause worsens outcomes after paediatric IHCA
Related Articles
February 17, 2021
High-dose influenza vaccine in patients with CVD
February 17, 2021
No CV benefit from omega 3 in high-risk patients
February 18, 2021
IV iron reduces HF hospitalisation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com